229 related articles for article (PubMed ID: 33001862)
1. Protein tyrosine phosphatase nonreceptor type 2 controls colorectal cancer development.
Katkeviciute E; Hering L; Montalban-Arques A; Busenhart P; Schwarzfischer M; Manzini R; Conde J; Atrott K; Lang S; Rogler G; Naschberger E; Schellerer VS; Stürzl M; Rickenbacher A; Turina M; Weber A; Leibl S; Leventhal GE; Levesque M; Boyman O; Scharl M; Spalinger MR
J Clin Invest; 2021 Jan; 131(1):. PubMed ID: 33001862
[TBL] [Abstract][Full Text] [Related]
2. Small-molecule PTPN2 Inhibitors Sensitize Resistant Melanoma to Anti-PD-1 Immunotherapy.
Zhu Z; Tang R; Huff S; Kummetha IR; Wang L; Li N; Rana TM
Cancer Res Commun; 2023 Jan; 3(1):119-129. PubMed ID: 36968224
[TBL] [Abstract][Full Text] [Related]
3. PTPN2 restrains CD8⁺ T cell responses after antigen cross-presentation for the maintenance of peripheral tolerance in mice.
Wiede F; Ziegler A; Zehn D; Tiganis T
J Autoimmun; 2014 Sep; 53():105-14. PubMed ID: 24997008
[TBL] [Abstract][Full Text] [Related]
4. Galectin-1 fosters an immunosuppressive microenvironment in colorectal cancer by reprogramming CD8
Cagnoni AJ; Giribaldi ML; Blidner AG; Cutine AM; Gatto SG; Morales RM; Salatino M; Abba MC; Croci DO; Mariño KV; Rabinovich GA
Proc Natl Acad Sci U S A; 2021 May; 118(21):. PubMed ID: 34006646
[TBL] [Abstract][Full Text] [Related]
5. Molecular and clinical characterization of PTPN2 expression from RNA-seq data of 996 brain gliomas.
Wang PF; Cai HQ; Zhang CB; Li YM; Liu X; Wan JH; Jiang T; Li SW; Yan CX
J Neuroinflammation; 2018 May; 15(1):145. PubMed ID: 29764444
[TBL] [Abstract][Full Text] [Related]
6. Th17 cells inhibit CD8
Wang D; Yu W; Lian J; Wu Q; Liu S; Yang L; Li F; Huang L; Chen X; Zhang Z; Li A; Liu J; Sun Z; Wang J; Yuan W; Zhang Y
J Hematol Oncol; 2020 Jun; 13(1):68. PubMed ID: 32503584
[TBL] [Abstract][Full Text] [Related]
7. IL-17 inhibits CXCL9/10-mediated recruitment of CD8
Chen J; Ye X; Pitmon E; Lu M; Wan J; Jellison ER; Adler AJ; Vella AT; Wang K
J Immunother Cancer; 2019 Nov; 7(1):324. PubMed ID: 31775909
[TBL] [Abstract][Full Text] [Related]
8. Reduced expression of phosphatase PTPN2 promotes pathogenic conversion of Tregs in autoimmunity.
Svensson MN; Doody KM; Schmiedel BJ; Bhattacharyya S; Panwar B; Wiede F; Yang S; Santelli E; Wu DJ; Sacchetti C; Gujar R; Seumois G; Kiosses WB; Aubry I; Kim G; Mydel P; Sakaguchi S; Kronenberg M; Tiganis T; Tremblay ML; Ay F; Vijayanand P; Bottini N
J Clin Invest; 2019 Mar; 129(3):1193-1210. PubMed ID: 30620725
[TBL] [Abstract][Full Text] [Related]
9. PTPN2 regulates the generation of exhausted CD8
LaFleur MW; Nguyen TH; Coxe MA; Miller BC; Yates KB; Gillis JE; Sen DR; Gaudiano EF; Al Abosy R; Freeman GJ; Haining WN; Sharpe AH
Nat Immunol; 2019 Oct; 20(10):1335-1347. PubMed ID: 31527834
[TBL] [Abstract][Full Text] [Related]
10. PTPN2 Deficiency Enhances Programmed T Cell Expansion and Survival Capacity of Activated T Cells.
Flosbach M; Oberle SG; Scherer S; Zecha J; von Hoesslin M; Wiede F; Chennupati V; Cullen JG; List M; Pauling JK; Baumbach J; Kuster B; Tiganis T; Zehn D
Cell Rep; 2020 Jul; 32(4):107957. PubMed ID: 32726622
[TBL] [Abstract][Full Text] [Related]
11. Colorectal Cancer Immune Infiltrates: Significance in Patient Prognosis and Immunotherapeutic Efficacy.
Guo L; Wang C; Qiu X; Pu X; Chang P
Front Immunol; 2020; 11():1052. PubMed ID: 32547556
[TBL] [Abstract][Full Text] [Related]
12. PTPN2 phosphatase deletion in T cells promotes anti-tumour immunity and CAR T-cell efficacy in solid tumours.
Wiede F; Lu KH; Du X; Liang S; Hochheiser K; Dodd GT; Goh PK; Kearney C; Meyran D; Beavis PA; Henderson MA; Park SL; Waithman J; Zhang S; Zhang ZY; Oliaro J; Gebhardt T; Darcy PK; Tiganis T
EMBO J; 2020 Jan; 39(2):e103637. PubMed ID: 31803974
[TBL] [Abstract][Full Text] [Related]
13. Benzoquinone, a leukemogenic metabolite of benzene, catalytically inhibits the protein tyrosine phosphatase PTPN2 and alters STAT1 signaling.
Duval R; Bui LC; Mathieu C; Nian Q; Berthelet J; Xu X; Haddad I; Vinh J; Dupret JM; Busi F; Guidez F; Chomienne C; Rodrigues-Lima F
J Biol Chem; 2019 Aug; 294(33):12483-12494. PubMed ID: 31248982
[TBL] [Abstract][Full Text] [Related]
14. Reversing tumor immune suppression with intratumoral IL-12: activation of tumor-associated T effector/memory cells, induction of T suppressor apoptosis, and infiltration of CD8+ T effectors.
Kilinc MO; Aulakh KS; Nair RE; Jones SA; Alard P; Kosiewicz MM; Egilmez NK
J Immunol; 2006 Nov; 177(10):6962-73. PubMed ID: 17082611
[TBL] [Abstract][Full Text] [Related]
15. NKTR-214 immunotherapy synergizes with radiotherapy to stimulate systemic CD8
Walker JM; Rolig AS; Charych DH; Hoch U; Kasiewicz MJ; Rose DC; McNamara MJ; Hilgart-Martiszus IF; Redmond WL
J Immunother Cancer; 2020 May; 8(1):. PubMed ID: 32457127
[TBL] [Abstract][Full Text] [Related]
16. Mitochondrial arginase-2 is a cell‑autonomous regulator of CD8+ T cell function and antitumor efficacy.
Martí i Líndez AA; Dunand-Sauthier I; Conti M; Gobet F; Núñez N; Hannich JT; Riezman H; Geiger R; Piersigilli A; Hahn K; Lemeille S; Becher B; De Smedt T; Hugues S; Reith W
JCI Insight; 2019 Nov; 4(24):. PubMed ID: 31751318
[TBL] [Abstract][Full Text] [Related]
17. Protein Tyrosine Phosphatase Non-Receptor Type 2 Function in Dendritic Cells Is Crucial to Maintain Tissue Tolerance.
Hering L; Katkeviciute E; Schwarzfischer M; Busenhart P; Gottier C; Mrdjen D; Komuczki J; Wawrzyniak M; Lang S; Atrott K; Becher B; Rogler G; Scharl M; Spalinger MR
Front Immunol; 2020; 11():1856. PubMed ID: 32973765
[TBL] [Abstract][Full Text] [Related]
18. T-Cell-Specific PTPN2 Deficiency in NOD Mice Accelerates the Development of Type 1 Diabetes and Autoimmune Comorbidities.
Wiede F; Brodnicki TC; Goh PK; Leong YA; Jones GW; Yu D; Baxter AG; Jones SA; Kay TWH; Tiganis T
Diabetes; 2019 Jun; 68(6):1251-1266. PubMed ID: 30936146
[TBL] [Abstract][Full Text] [Related]
19. PTPN2 in the Immunity and Tumor Immunotherapy: A Concise Review.
Song J; Lan J; Tang J; Luo N
Int J Mol Sci; 2022 Sep; 23(17):. PubMed ID: 36077422
[TBL] [Abstract][Full Text] [Related]
20. Increased CD8 Tumor Infiltrating Lymphocytes in Colorectal Cancer Microenvironment Supports an Adaptive Immune Resistance Mechanism of PD-L1 Expression.
Sudoyo AW; Kurniawan AN; Kusumo GD; Putra TP; Rexana FA; Yunus M; Budiyati AD; Kurniawan D; Utama A; Utomo AR
Asian Pac J Cancer Prev; 2019 Nov; 20(11):3421-3427. PubMed ID: 31759368
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
